Peptide · Fact sheet
Pramlintide
Also known as Symlin · pramlintide acetate
Pramlintide is FDA approved as Symlin for certain people with type 1 or type 2 diabetes who use mealtime insulin and have not reached glycemic goals. It is not FDA approved as a stand-alone obesity medicine.
What is Pramlintide?
Pramlintide is a manufactured analog of amylin, a peptide hormone normally released with insulin after eating.
Amylin signaling affects stomach emptying, glucagon release, satiety, and blood glucose, which also made the pathway important in obesity-drug research.
Benefits people look for
It is the established clinical proof that amylin biology can be used therapeutically.
Weight changes in diabetes and older obesity trials helped motivate longer-acting amylin analogs such as cagrilintide, but the molecules and evidence are not interchangeable.
What the evidence supports
- Controlled diabetes trials showed improved glycemic outcomes when pramlintide was added in the labeled setting.
- Older obesity trials found weight-loss signals, but pramlintide did not become a stand-alone FDA-approved obesity medicine.
All research areas
- Glucose control with mealtime insulin
- Satiety and food intake
- Obesity and weight outcomes
- Obesity treatment outside the approved diabetes context
- Amylin-based combination medicines
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The label carries a boxed warning for severe hypoglycemia when used with mealtime insulin, especially in type 1 diabetes.
- Nausea and other gastrointestinal effects are common.
- Its approved use requires clinical management that cannot be generalized to consumer weight-loss use.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesRandomized trials support the scoped diabetes indication. Obesity research without insulin-treated diabetes is older and does not create a current stand-alone weight-management approval.
Selected research to read
Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.
Older exploratory obesity study that does not establish an approved stand-alone use.
FDA approval & research status
Symlin is FDA approved as an adjunct for selected adults with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite appropriate insulin management.
Approved uses covered here
- Adjunctive treatment in the insulin-treated diabetes populations specified by the Symlin label
FDA approved as an adjunct diabetes medicine
Pramlintide is approved under the Symlin label for specified insulin-treated diabetes populations. Its investigational weight history does not create a weight-loss approval.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether pramlintide has a useful modern obesity role compared with other agents
- Long-term outcomes for unapproved weight-management use
- How benefits and harms compare with longer-acting amylin analogs
- Which combination strategies, if any, will prove clinically superior
The takeaway
Pramlintide validates amylin as a therapeutic pathway, but its real approval is a narrow diabetes adjunct—not general weight loss.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Symlin
Approved population, boxed warning, adverse reactions, and clinical evidence.
- 2pubmedOne-year randomized pramlintide diabetes trial
Controlled evidence for glycemic and weight outcomes in insulin-treated type 2 diabetes.
- 3pubmedRandomized pramlintide obesity study
Older exploratory obesity study that does not establish an approved stand-alone use.